P. A. Dennis

Akt/protein kinase B is constitutively active in non-small cell lung cancer cells and promotes cellular survival and resistance to chemotherapy and radiation.

P. Dennis, J. Brognard, A. Clark, 2001, Cancer research.

Brognard J, Dennis PVariable apoptotic response of NSCLC cells to inhibition of the MEK/ERK pathway by small molecules or dominant negative mutants. Cell Death Differ 9: 893-904

J. Brognard, P. A. Dennis, Dennis Pa, 2002 .

Evidence of ultraviolet type mutations in xeroderma pigmentosum melanomas

Sikandar G. Khan, M. Raffeld, M. C. Hollander, 2009, Proceedings of the National Academy of Sciences.

Variable apoptotic response of NSCLC cells to inhibition of the MEK/ERK pathway by small molecules or dominant negative mutants

J. Brognard, P. A. Dennis, Phillip A. Dennis, 2002, Cell Death and Differentiation.

Activated forms of H-RAS and K-RAS differentially regulate membrane association of PI3K, PDK-1, and AKT and the effect of therapeutic kinase inhibitors on cell survival.

P. Dent, M. Hagan, A. Yacoub, 2005, Molecular cancer therapeutics.

Cellular activation of latent transforming growth factor beta requires binding to the cation-independent mannose 6-phosphate/insulin-like growth factor type II receptor.

D. Rifkin, P. Dennis, P. A. Dennis, 1991, Proceedings of the National Academy of Sciences of the United States of America.